Eloxx Pharmaceuticals, Inc. (ELOX) – What Are Analysts Thinking About This Stock?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $38.33.

A number of research analysts have commented on the company. Lifesci Capital started coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price target for the company. Lucid Cap Mkts raised Eloxx Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 20th. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Eloxx Pharmaceuticals in a research note on Monday, August 24th. Weiss Ratings began coverage on Eloxx Pharmaceuticals in a report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Finally, Leerink Partners set a $32.00 target price on Eloxx Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, September 18th.

Eloxx Pharmaceuticals Stock Performance

NASDAQ:ELOX opened at $12.50 on Tuesday. The stock has a market capitalization of $50.45 million, a P/E ratio of -8.12 and a beta of -1,960.42. The company has a 50 day moving average price of $16.23 and a 200 day moving average price of $15.31. Eloxx Pharmaceuticals has a fifty-two week low of $8.20 and a fifty-two week high of $23.40.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter. Research analysts forecast that Eloxx Pharmaceuticals will post -2.61 earnings per share for the current fiscal year.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. These mutations can cause cells to stop producing functional proteins, potentially leading to serious inherited disorders.

The company’s lead program, ELX-02, was a synthetic aminoglycoside designed to promote ribosomal read-through of premature stop signals in messenger RNA. Eloxx evaluated ELX-02 in clinical development for genetic conditions including cystinosis and explored its potential in other diseases involving nonsense mutations.

Eloxx also developed ZKN-013, an oral small-molecule program intended to address nonsense-mutation disorders.